NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC

Strategic acquisition places NexTel at the forefront of precision neuro-restoration by integrating Xycota’s exosome-delivered brain circuitry repair platform. The deal is further supported by Xycota’s pending FDA Orphan Drug Designation, which can enhance development/treatment incentives if granted.

Analysis

Strategic acquisition places NexTel at the forefront of precision neuro-restoration by integrating Xycota’s exosome-delivered brain circuitry repair platform. The deal is further supported by Xycota’s pending FDA Orphan Drug Designation, which can enhance development/treatment incentives if granted.